Israel Active

Israel’s Nanox (reported previously) has signed multiple new deals to deploy over 1000 of its mobile X-ray devices to , and .  Previous deployments include to Japan, Australia, New Zealand, Norway, South Korea and Vietnam.

An exciting article about a United Hatzalah paramedic who, on the eve of her final chemistry exam, rushed to save the life of a heart-attack victim.

The latest Ben-Gurion Briefing, “Autism Research and Treatment” featured 4 leading Israeli experts from Ben-Gurion University and Soroka University Medical Center. They discussed whether early autism diagnosis can lead to the eradication of symptoms of autism later in life.

At its Israeli R&D center, C2i Genomics has developed a personalized, real-time solution for monitoring recurrence and treatment response for various types of solid cancers. It employs a breakthrough tumor DNA pattern recognition approach for liquid biopsy.

The US FDA has awarded breakthrough designation to the VasQ from Israel’s Laminate Medical (reported previously). The device provides safe connections to dialysis machines.

Gastro stents are essential for clearing clots in the bile ducts and pancreas. Israel’s Endo GI Medical has received US FDA approval for its Stenting Placement Delivery Systems that reduce risk of infection from repetitive insertions of singular stents.

Neuroscientists at Tel Aviv University working with others at Israel’s Weizmann Institute, UK’s Bristol and France’s Montpellier universities, have discovered the brain’s mechanism for deep sleep. The locus coeruleus in the brainstem secretes the chemical noradrenaline and too high levels prevent deep sleep.

Researchers at Israel’s Technion Institute have made a breakthrough discovery that cancer progresses much faster in patients with heart problems. To improve their survival chances, these patients should have their heart treated first before beginning cancer therapy.

Israel’s AID Genomics has developed a coronavirus test kit that gives results in just 30 minutes. It uses different enzymes from current tests with much higher sensitivity. AID Genomics has partnered with the Chinese-owned BGI Group, which will be distributing the test in Israel and globally.

Israeli-founded AZTherapies is in Phase 3 trials for its ALZT-OP1 for Alzheimer’s disease. The treatment also suppresses the immune system’s “cytokine storm” that is often lethal to Covid-19 infected patients. AZTherapies is building commercial partnerships with Israeli institutions.